Pulmonary Toxicity in Patients Treated with Gemcitabine and Taxanes
Author Information
Author(s): Czarnecki A, Voss S
Primary Institution: Eli Lilly and Company Limited
Hypothesis
Do gemcitabine and taxane combinations have greater pulmonary toxicity than single agents?
Conclusion
There is no substantial difference in pulmonary toxicity reported with the combination of gemcitabine and taxanes compared to gemcitabine alone.
Supporting Evidence
- The review of pulmonary toxicity cases indicated no substantial difference between gemcitabine alone and in combination with taxanes.
- Proportional Reporting Ratios showed similar patterns for pulmonary toxicity across all three drugs.
Takeaway
This study looked at whether combining certain cancer drugs causes more lung problems than using them alone, and found that they are about the same.
Methodology
The study analyzed adverse drug reaction reports from a safety database and calculated Proportional Reporting Ratios for pulmonary toxicity.
Limitations
The study relied on postmarketing data, which may not capture all cases of pulmonary toxicity.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website